BACKGROUND: High serum carcinoembryonic antigen (CEA) levels have been reported to be associated with poor prognosis in non-small cell lung cancer (NSCLC), while the prognostic role of tumor CEA expression remains to be defined. The present study investigated the expression of tumor CEA in stage IB NSCLC, and correlated it with clinicopathological features and prognosis. PATIENTS AND METHODS: Immunohistochemistry for tumor CEA was assessed in the specimens of 183 patients with stage IB NSCLC. Receiver-operating characteristic (ROC) curve analysis was used to determine the cut-off score for tumor positivity. RESULTS: High CEA expression was detected more frequently in adenocarcinomas (72.2%) and other NSCLCs (69.0%) than in squamous cell carcinomas (25.4%, P<0.001). Both univariate and multivariate analysis indicated that tumor CEA was an independent prognostic factor for overall and disease-free survival (P<0.05). CONCLUSIONS: Elevated expression of tumor CEA may be an adverse prognostic indicator in stages IB NSCLC.
BACKGROUND: High serum carcinoembryonic antigen (CEA) levels have been reported to be associated with poor prognosis in non-small cell lung cancer (NSCLC), while the prognostic role of tumorCEA expression remains to be defined. The present study investigated the expression of tumorCEA in stage IB NSCLC, and correlated it with clinicopathological features and prognosis. PATIENTS AND METHODS: Immunohistochemistry for tumorCEA was assessed in the specimens of 183 patients with stage IB NSCLC. Receiver-operating characteristic (ROC) curve analysis was used to determine the cut-off score for tumor positivity. RESULTS: High CEA expression was detected more frequently in adenocarcinomas (72.2%) and other NSCLCs (69.0%) than in squamous cell carcinomas (25.4%, P<0.001). Both univariate and multivariate analysis indicated that tumorCEA was an independent prognostic factor for overall and disease-free survival (P<0.05). CONCLUSIONS: Elevated expression of tumorCEA may be an adverse prognostic indicator in stages IB NSCLC.
Authors: S-U Han; T-H Kwak; K H Her; Y-H Cho; C Choi; H-J Lee; S Hong; Y S Park; Y-S Kim; T-A Kim; S-J Kim Journal: Oncogene Date: 2007-07-23 Impact factor: 9.867
Authors: Hannah Fuellgraf; Oliver Schilling; Zon Weng Lai; Birte Kulemann; Sylvia Timme; Frank Makowiec; Jasmin H Shahinian; Jens Hoeppner; Martin Werner; Ulrich T Hopt; Ulrich F Wellner; Peter Bronsert Journal: J Cancer Date: 2017-02-25 Impact factor: 4.207